Citation Impact
Citing Papers
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
Overexpression of GlutathioneS-Transferase II and Multidrug Resistance Transport Proteins Is Associated with Acquired Tolerance to Inorganic Arsenic
2001
RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells
2010
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
1999
Tipin-Replication Protein A Interaction Mediates Chk1 Phosphorylation by ATR in Response to Genotoxic Stress
2010 StandoutNobel
Ferroptosis as a p53-mediated activity during tumour suppression
2015 StandoutNature
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
2009 Standout
Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer
2012 StandoutNobel
l-S,R-buthionine sulfoximine: historical development and clinical issues
1998
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
2008
C-type lectins in immunity and homeostasis
2018
Reconstitution of Human Claspin-mediated Phosphorylation of Chk1 by the ATR (Ataxia Telangiectasia-mutated and Rad3-related) Checkpoint Kinase
2009 StandoutNobel
The DNA Damage Response Kinases DNA-dependent Protein Kinase (DNA-PK) and Ataxia Telangiectasia Mutated (ATM) Are Stimulated by Bulky Adduct-containing DNA
2011 StandoutNobel
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
2005
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
The x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases
2008
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
2005 StandoutNature
ESDN, a Novel Neuropilin-like Membrane Protein Cloned from Vascular Cells with the Longest Secretory Signal Sequence among Eukaryotes, Is Up-regulated after Vascular Injury
2001 StandoutNobel
Single-cell technologies for monitoring immune systems
2014
Cancer genes and the pathways they control
2004 Standout
Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia
2004
Targeting multidrug resistance in cancer
2006 Standout
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
2020 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Noninvasive Bioluminescence Imaging in Small Animals
2008
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
Malignant Gliomas in Adults
2008 Standout
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Hematopoietic Stem-Cell Transplantation
2006 Standout
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
2011 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Overview of the clinical efficacy of investigational anticancer drugs
2003
Enhanced Phagocytosis through Inhibition of de Novo Ceramide Synthesis
2003 StandoutNobel
Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia
2001
Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome
2004
Neuroblastoma
2007 Standout
Sulfasalazine-Induced Reduction of Glutathione Levels in Breast Cancer Cells: Enhancement of Growth-Inhibitory Activity of Doxorubicin
2007
Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines
2008
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
2017 Standout
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia:
2004
Development of Multidrug-Resistance Convertors: Sense or Nonsense?
2000
Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals
1995
Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters
2005
A novel TNF-inducible message with putative growth suppressor function
1999
Tethering DNA Damage Checkpoint Mediator Proteins Topoisomerase IIβ-binding Protein 1 (TopBP1) and Claspin to DNA Activates Ataxia-Telangiectasia Mutated and RAD3-related (ATR) Phosphorylation of Checkpoint Kinase 1 (Chk1)
2011 StandoutNobel
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
2003
Basic Principles and Emerging Concepts in the Redox Control of Transcription Factors
2011
Protein Promiscuity in H 2 O 2 Signaling
2018
Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)
2004
The Role of ABC Transporters in Clinical Practice
2003
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Tumour stem cells and drug resistance
2005 Standout
Emerging DNA topoisomerase inhibitors as anticancer drugs
2004
Breast Cancer Resistance Protein in Drug Resistance of Primitive CD34+38− Cells in Acute Myeloid Leukemia
2005
5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity
2007 StandoutNobel
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Multidrug resistance protein attenuates gemtuzumab ozogamicin–induced cytotoxicity in acute myeloid leukemia cells
2003
Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621
2004
Breast Cancer Resistance Protein (BCRP) in Acute Leukaemia
2003
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study
1997
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2
2005
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Germinal center B cell development has distinctly regulated stages completed by disengagement from T cell help
2017
Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors
2004
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1
2001
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance
2007
Functions of Ceramide in Coordinating Cellular Responses to Stress
1996 StandoutScience
Structural and Biochemical Studies of a Fluoroacetyl-CoA-Specific Thioesterase Reveal a Molecular Basis for Fluorine Selectivity
2010 StandoutNobel
Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
2001
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies
2004
B cell–intrinsic TBK1 is essential for germinal center formation during infection and vaccination in mice
2021 StandoutNobel
Cellular uptake of nanoparticles: journey inside the cell
2017 Standout
Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition
2004
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Management of Acute Myelogenous Leukemia in the Elderly
2003
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
2004 StandoutNobel
Real-Time Bioluminescence Imaging of Glycans on Live Cells
2010 StandoutNobel
Catalytic Asymmetric Conjugate Addition of Indolizines to α,β‐Unsaturated Ketones
2017 StandoutNobel
Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia
2003
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
1996 StandoutScience
Works of Hans Minderman being referenced
Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
1993
Peroxiredoxin 1 Stimulates Secretion of Proinflammatory Cytokines by Binding to TLR4
2009
PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein.
1996
Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023
2004
Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells
2000
Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function
2004
The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells
2006
Characterization of Protein Kinase chk1 Essential for the Cell Cycle Checkpoint after Exposure of Human Head and Neck Carcinoma A253 Cells to a Novel Topoisomerase I Inhibitor BNP1350
2000
Flow cytometric analysis of breast cancer resistance protein expression and function
2002
Quantifying nuclear p65 as a parameter for NF‐κB activation: Correlation between ImageStream cytometry, microscopy, and Western blot
2011
DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux
1996
Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
1998
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
2002
VX-710 (Biricodar) Increases Drug Retention and Enhances Chemosensitivity in Resistant Cells Overexpressing P-Glycoprotein, Multidrug Resistance Protein, and Breast Cancer Resistance Protein
2004
Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator
2005
Rational design of irinotecan administration based on preclinical models.
1998
Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis.
1998
Simultaneous, Single‐Cell Measurement of Messenger RNA, Cell Surface Proteins, and Intracellular Proteins
2016
Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes
2016
Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies.
1989
Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
2003
d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
1996
In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells
2005